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Abstract: Uncoupling proteins (UCPs) belong to a family of mitochondrial carrier proteins 
that are present in the mitochondrial inner membrane. UCP1 was first identified followed 
by  its  two  homologs,  UCP2  and  UCP3.  The  physiological  functions  of  UCP  include 
lowering  mitochondrial  membrane  potential  and  dissipating  metabolic  energy  as  heat. 
However, UCP can be dysregulated and may contribute to the pathogenesis of metabolic 
disorders and obesity. Recent studies suggest that UCP also plays a role in neurodegenerative 
diseases  and  atherosclerosis.  In  addition,  the  widely  expressed  UCP,  UCP2,  has  been 
shown to be upregulated in a number of aggressive human cancers. One mechanism of 
UCP2 upregulation in these cancers is due to oxidative stress, and elevated UCP2 in turn 
reduces oxidative stress, which provides a growth advantage for these cancers. Nevertheless, 
new  studies  suggest  UCP2  may  interact  with  oncogenes  and  tumor  suppressor  genes, 
providing a potential new mechanism of how UCP2 contributes to cancer development. In 
this review, the evidence supporting the role of UCPs in diseases other than diabetes and 
obesity, the reports on how UCP is regulated in cancer cells, and how UCP may regulate 
p53 will be discussed. 
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1. Introduction 
In vertebrates, energy is mainly produced in the mitochondria via the Citric Acid Cycle coupled 
with  oxidative  phosphorylation.  The  mitochondrial  respiration  process  generates  a  proton  gradient 
across the mitochondrial inner membrane that establishes the electrochemical potential (Δψm), which is 
mainly used for ATP synthesis. However, not all of the energy available in the electrochemical gradient 
is coupled to ATP synthesis. Some of the energy is consumed by “proton leak” reactions, by which 
protons pumped into the inner membrane space flow back into the matrix through proton conductance 
pathways in the inner membrane that bypass the ATP synthase. As a result, energy derived from the 
metabolic  oxidation  reaction  is  dissipated  as  heat  [1–4].  This  nonproductive  proton  leak,  termed 
mitochondrial  uncoupling,  is  physiologically  important  and  accounts  for  20–25%  of  the  basal 
metabolic rate [5,6]. 
Mitochondrial uncoupling is mediated mainly by uncoupling proteins (UCPs), among those, UCP1 
is the first to be identified in brown adipose tissue [7], followed by its four homologs: UCP2 [8] is 
ubiquitously  expressed,  UCP3  [9]  exists  solely  in  skeletal  muscle  and  the  heart,  UCP4  [10],  and 
BMCP1  (brain  mitochondrial  carrier  protein-1,  [11]) or  UCP5  are  predominantly  expressed  in  the 
central  nervous  system.  UCPs  are  anion  carriers  across the  mitochondrial  inner  membrane,  which 
bring  protons  back  into the  mitochondrial  matrix.  In  addition,  UCP1  dissipates  redox  energy  and 
thereby provides heat to the animal. UCP2 decreases the production of reactive oxygen species [12]. 
Furthermore, it has been suggested that brain-specific UCP4 and UCP5 play a role in apoptosis in the 
brain [13,14]. 
2. UCPs and Non-Cancer Diseases 
Mitochondria-generated  ATP  provides  the  major  fuel  for  eukaryotic  cells.  As  byproducts,  free 
radicals can be generated within mitochondria during energy production, which could harm cells if not 
rapidly  removed.  Mild  mitochondrial  uncoupling  can  reduce  the  generation  of  free  radicals  and 
therefore, protect cells. Mitochondrial uncoupling has been amplified or reduced during the pathogenesis 
of  a  number  of  human  diseases  due  to  up-  or  down-regulation  of  UCP.  The  two  most  studied 
UCP-associated diseases are diabetes and obesity, and studies of UCP in these two diseases have been 
thoroughly reviewed. 
Non-alcoholic fatty liver disease is another form of metabolic disorder. Park et al. detected UCP2 in 
young Asian patients, and the results showed that the expression levels of UCP2 were correlated with 
general pathologic severity [15]. 
Non-alcoholic steatohepatitis (NASH) has been identified in patients with non-alcoholic fatty liver 
disease with evidence of inflammation in liver biopsies. The mechanistic progression of non-alcoholic 
fatty liver disease to non-alcoholic steatohepatitis is not clear; however the involvement of underlying 
mitochondrial dysfunction orchestrates the progression due to its role in fatty acid oxidation, ROS 
generation  and  ATP  synthesis.  NASH  has  been  characterized  by  the  accumulation  of  fatty  acids   
in  hepatocytes  and  oxidative  stress  [16],  decreased  ATP  production  [17],  and  the  induction  of 
proinflammatory cytokines [18]. Serviddio et al. reports that the upregulation of UCP2 protects the 
liver  from  excessive  fat  accumulation,  but  chronically  depletes  the  liver  of  ATP,  compromising   Int. J. Mol. Sci. 2011, 12  5287 
 
 
the  response  of  the  liver  to  acute  energy  demands,  which  results  in  increased  susceptibility  to 
ischemia-reperfusion injury [19]. 
Clinical  evidence  suggests  that  UCPs  may  be  associated  with  diseases  distinct  from  metabolic 
diseases.  For  instance,  higher  expression  levels  of  UCP2  may  mediate  follicle  development  in 
polycystic ovary syndrome [20]. Several well designed studies further suggest that UCP is involved in 
the pathogenesis of neurodegenerative disease, atherosclerosis, liver disease, etc.   
Richard et al. reported the presence of UCP2 mRNA with varying intensities throughout the brain. 
Marked high  intensities were  found  in the hypothalamus, the ventral septal region,  the ventricular 
region and the cerebellum, suggesting a novel role of UCP in modulating neuroendocrine functions 
and autonomic responses of the brain [21]. In addition, UCP2-mediated mitochondrial proton leak has 
been positively correlated with increased oxygen consumption in brain tissues [22].This regulation of 
oxygen consumption, suggests that UCP2 may modulate ROS production and influence the process of 
neurodegeneration [21]. 
The  mRNA  expression  of  UCP2  in  the  brain  suggested  neuronal  localization  [21].  In  an   
animal  model  of  Parkinson’s  disease  (PD),  in  which  dopamine  neurons  are  depleted  by 
1-methyl-4-phenyl-1,2,5,6  tetrahydropyridine  (MPTP),  UCP2  knockout  increased  whereas  UCP2 
overexpression decreased MPTP-induced nigral dopamine cell loss. Coenzyme Q10 (CoQ10), a cofactor 
of  mitochondrial  metabolism  and  UCP2  activity  [23],  induced  UCP2-mediated  mitochondrial 
uncoupling in the substantia nigra [24]. When given orally, CoQ10 was shown to reduce dopamine cell 
loss in both mouse [25] and primate models of PD [24] and potentially slowed the progression of the 
disease in human patients [26]. As mentioned above, UCP2 protects against dopamine cell loss caused 
by the mitochondrial complex I toxin MPTP. Consistent with that, degeneration of substantia nigra 
compacta dopaminergic neurons in human PD is associated with mitochondrial complex I dysfunction 
and free radical toxicity [27]. These studies demonstrate the importance of UCP2 in normal nigral 
dopamine  cell  metabolism,  and  suggest  that  UCP2  is  important  in  regulating  cell  survival  and 
susceptibility to mitochondrial toxins; and may serve as a novel therapeutic target for the prevention 
and treatment of PD [28].   
Not surprising,  UCP also plays  an  important role  in Alzheimer’s disease (AD). The expression 
levels of UCP2, 4, and 5 were significantly reduced  in AD patients, which were accompanied  by 
upregulation of nitric oxide synthases (NOS), and resulted in increased oxidative stress and impaired 
mitochondrial functions. Therefore, to increase the expression level of UCP may help in the treatment 
of AD [29]. 
The protective role of UCP2 against atherosclerosis was demonstrated using irradiated low-density 
lipoprotein receptor-deficient mice (LDLR-/-). These mice were transplanted with bone marrow from 
either UCP2 deficient mice or wild-type mice, and fed with an atherogenic diet. The results showed 
that the atherosclerotic lesion size was markedly increased in the mice receiving UCP2 deficient bone 
marrow, which was accompanied by enhanced oxidative stress [30]. 
3. UCP and Cancer 
Compared with the extensive studies on UCP in diabetes and obesity, the role of UCP (mostly 
UCP2) in cancer was recently recognized and has attracted more attention. As a matter of fact, the Int. J. Mol. Sci. 2011, 12  5288 
 
 
impact of mitochondrial uncoupling on cellular physiology is not restricted to normal cells; it also 
plays an important role in the reprogramming of cancer cell metabolism [31]. 
Early evidence showing that UCP might be important for tumor growth arises  from rats which 
received an inoculation of the Yoshida AH-130 ascites hepatoma cells [11]. The expression levels of 
both UCP2 and UCP3 mRNAs were increased, suggesting that energy expenditure is associated with 
tumor growth. 
In  human  studies,  most  of  the  results  point  to  UCP2  potentially  being  associated  with  the 
development  of  colon  and  breast  cancer.  Horimoto  et  al.  reported  that  UCP2  overexpression  in 
malignancy was limited to the colon [32], in which UCP2 expression in human colon tissue increased 
with  the  degree  of  neoplasia.  However,  their  results  also  showed  that  high  UCP2  levels  in  colon 
adenocarcinoma correlated with high oxidant levels, making it hard to explain whether it is a cause or 
effect relationship between uncoupling and oxidative stress.   
Kuai et al. further demonstrated that the levels of both UCP2 mRNA and protein were higher in 
colon cancer tissue samples than in its adjacent tissue samples [33], and the authors suggested that 
increased UCP2 expression may be involved in colon cancer metastasis.   
However, the first colon tumorigenesis study using UCP2 null mice showed surprising results [34]. 
The  UCP2  null  mice  developed  more  colon  tumors  than  the  wild-type  controls  with  increased 
oxidative  stress  and  enhanced  NF-κB  activation  when  treated  with  azoxymethane  (AOM),  an 
experimental alkylating carcinogen [35], despite the fact that isolated mitochondria from UCP2-/- cells 
produced more superoxide/hydrogen peroxide. In our opinion, this study can be improved by checking 
whether UCP2 is up- or down-regulated during colon tumorigenesis in the wild-type mice. If it is 
upregulated,  then  UCP2  transgenic  mice  might  be  a  better  tool  to  study  the  role  of  UCP2  in   
colon tumorigenesis. 
Later studies suggest that UCP2 is also involved in the pathogenesis of other cancers. Sayeed et al. 
reported a significant association of UCP2 with tumor grade in primary breast cancer [36]. The results 
are reinforced by the study from Won et al., which demonstrated that UCP2 expression was correlated 
significantly  with  histological  grade  and  mitotic  count  in  invasive  ductal  carcinoma  of  the  breast 
analyzed from human tissue microarrays [37]. 
We  used  a  tumor  promotion  model  to  study  the  role  of  mitochondrial  uncoupling  in  tumor 
promotion [38]. Our study demonstrated that mitochondrial uncouplers inhibited cell death that arose 
during tumor promotion. When UCP2 was downregulated using a siRNA approach, cell transformation 
was suppressed, suggesting UCP2 may serve as a tumor promoter during early tumorigenesis.   
Another important role of UCPs in cancer is their contributions to chemoresistance [39,32]. UCPs 
were  upregulated  in  many  chemoresistant  cancer  cell  lines,  which  may  provide  a  prosurvival 
advantage  to  tumor  cells  via  attenuating  ROS  (reactive  oxygen  species)  generation  [40–42],  and 
increasing drug concentrations to kill these cancer cells [43].   
4. Regulation of UCP in Cancer Cells 
UCP gene regulation is not well understood. UCP can be generally regulated by oxidative stress. 
When oxidative stress occurs, UCP2 and UCP3 uncoupling activities can be stimulated by superoxide 
anion,  limiting  ROS  production  by  the  mitochondrial  respiratory  chain.  This  in  turn  decreases 
superoxide levels and UCP uncoupling activity via a feedback loop [44]. Fatty acids also induced Int. J. Mol. Sci. 2011, 12  5289 
 
 
UCP2  and  UCP3  in  muscle  [45]  and  fat  [46],  which  was  mediated  by  transcription  factors  of 
peroxisome proliferator-activated receptors (PPAR, [47]). 
How oncogenes and tumor suppressor genes may regulate UCP should be of great interest to study 
UCP in cancer. However, such evidence is rare, which deserves more research efforts, since knowing 
the basic  biology of UCP regulation  in cancer cells  is essential  for potential UCP-targeted cancer 
therapy. One important study utilized well-to-moderately differentiated primary breast tumor cell lines 
showed  that  SMAD  was  recruited  to  the  UCP2  promoter  region  via  the  transforming  growth 
factor-beta (TGFβ)/SMAD-dependent pathway [36]. In contrast, in TGFβ-resistant high-grade tumors, 
potentiation of UCP2 repression fails to occur, contributing to impaired cell differentiation. 
5. UCP2 and p53 Signaling 
p53, as a pivotal tumor suppressor, can cause apoptotic cell death in response to cellular stress 
stimuli (e.g., drugs, irradiation, UV, hypoxia) and the expression of viral or cellular oncogenes [48]. 
Interestingly,  a  fraction  of  p53  can  translocate  to  mitochondria  under  the  above  mentioned  stress 
conditions [49]. Similarly to nuclear p53, mitochondrial p53 is also able to initiate apoptosis [50]. 
Since both p53 and UCP2 can regulate and respond to oxidative stress, it is possible that there is a 
potential interaction between these two proteins. 
A few studies have suggested that this may indeed occur. Derdak et al. demonstrated that UCP2 
inhibited  apoptosis  of  colon  cancer  cells  by  suppressing  the  phosphorylation  of  p53  within  the 
transactivating  domain  via  suppressing  ROS  [43].  Won  et  al.  had  a  different  observation.  They 
reported that high UCP2 expression in invasive breast ductal carcinoma was associated with high p53 
nuclear expression [37]. However, the antibody against p53 used (DO-7) can detect both wild-type and 
mutant p53, and p53 is highly mutated in these tumors [51]. Therefore, it is not clear if the highly 
expressed p53 was wild-type or mutant or both. 
Our  studies  using  the  skin  carcinogenesis  model  revealed  that  during  early  tumor  promotion,   
the  tumor  suppressor  p53  translocated  to  mitochondria  and  physically  interacted  with  a  primary 
antioxidant defense enzyme, manganese superoxide dismutase (MnSOD), leading to suppression of its 
superoxide scavenging activity, as well as, increases in ROS levels [52]. Thus, in addition to the direct 
apoptotic  activity  of  mitochondria  p53,  the  ability  to  induce  ROS  accumulation  might  serve  as  a 
positive feed-back loop and play an essential role in the p53-mediated apoptosis pathway. 
Given  these  facts,  we  further  examined  the  role  of  UCP2  in  tumor  promoter-induced  p53 
mitochondrial  translocation  and  cell  transformation.  Downregulation  of  UCP2  expression  using  a 
transfection  with  specific  siRNA  to  UCP2  induced  translocation  of  a  small  amount  of  p53  to 
mitochondria, and also enhanced tumor promoter-induced p53 mitochondrial translocation whereas 
cell transformation was reduced [38]. These data indicated that UCP2-mediated mild mitochondrial 
uncoupling may serve as a tumor promoting event. 
The  elevated  levels  of  UCP2  in  cancer  cells  may  be  a  result  of  long-term  selection  during 
tumorigenesis,  since  any  event  that  results  in  UCP2  upregulation  could  help  cells  escape  from 
apoptosis mediated by the p53 signaling. Given the fact that mitochondrial uncoupling could cause 
dissipation of the mitochondrial potential, a decrease in mitochondrial ROS, and a reduction in p53’s 
response to oxidative stress, it is reasonable to propose that mitochondrial uncoupling may provide 
cancer cells with a prosurvival advantage via suppressing the p53 mediated apoptosis pathway. Int. J. Mol. Sci. 2011, 12  5290 
 
 
6. Conclusions 
It has been suggested that dysregulation of UCP is involved in the pathogenesis of not only diabetes 
and obesity, but also neurodegenerative disease, atherosclerosis, and cancer. Among these diseases, it 
is very likely that UCP can protect against neurodegeneration, but exacerbate the progression of the 
other diseases. In cancer, elevated UCP contributes not only to chemoresistance, but also to early 
transformation.  Therefore,  targeting  UCP  could  serve  as  a  promising  approach  for  both  cancer 
prevention and therapy. 
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